background

  • Glaucoma is a leading cause of global irreversible blindness. In 2018, 130 million people worldwide were estimated to have Glaucoma or ocular hypertension, a number expected to grow to 148 million by 2023. Glaucoma treatment is targeted to reduce elevated IOP (intra-ocular pressure). Medications, the first line therapy, are associated with compliance issues, side effects, diminishing effect and long-term costs. Subsequent lines of therapy are costly and require repeat procedures (laser) or highly invasive and associated with intra- and post-operative complications (filtration surgery). Micro invasive Glaucoma surgery (MIGS) is a recent, promising approach for Glaucoma treatment, aiming to lower IOP in a safer, minimally traumatic and medication-sparing manner. MIMS® is one of the leading alternatives in this category due to its simplicity and the fact it is stent-less. 
     
    The disease manifests as a progressive, chronic optic neuropathy with a loss of retinal ganglion cells and their axons, resulting in atrophy of the optic nerve and loss of visual function that can eventually lead to blindness. Its prevalence increases exponentially with age, but risk factors also include family history, ethnicity, central corneal thickness, myopia and increased intraocular pressure (IOP). The higher the IOP, the greater the likelihood of visual field loss, optic nerve damage and blindness. Elevated IOP is the only risk factor that can be addressed with therapies such as medications or Glaucoma surgery. Managing IOP early in the disease process has been shown to delay or even arrest Glaucoma progression and the resultant visual field loss.